Our results demonstrated that cGAMP treatment could improve living state of tumour-bearing mice, reduce the secretion of G-CSF by 4T1 tumour cells and alleviate the phenomenon of splenomegaly, which may be beneficial to tumour metastasis inhibition. Here, CSF3 is linked to Splenomegaly.